Harvard-based Xfund raises $73M in venture cash; Alexion shifts Euro base to Zurich;

@FierceBiotech: Meet some of the revolutionaries in biotech R&D. Report | Follow @FierceBiotech

@JohnCFierce: AbbVie to Shire: Maybe we should reconsider that $54B merger deal after all - $SHPG down 27%. Article | Follow @JohnCFierce

@DamianFierce: Fantastically timed press release: "Shire Announces the Organize Your Stuff Contest Winners." Release | Follow @DamianFierce

@EmilyMFierce: These 10 drugs could stop Ebola. Feature | Follow @EmilyMFierce

> The Harvard-based venture group Xfund has raised $73 million, according to documents filed with the SEC. Headed by Harvard grad Patrick Chung, Xfund set out a couple of years ago to back tech startups in the Cambridge/Boston hub. Their investment portfolio includes the med tech incubator Rock Health. "There are basically two approaches to venture capital investing," Xfund Partner Harry Weller, also General Partner of New Enterprise Associates, told a Harvard writer. "One is to 'spray and pray,' and the other is to make fewer, more selective investments. We back big, bold experiments." Statement

> Fast-growing Alexion Pharmaceuticals ($ALXN) is moving a large number of staffers at its European HQ now in Lausanne to Zurich. Bloomberg reports that the canton offers the lowest tax rate in the country. Story

Medical Device News

@FierceMedDev: Who are today's leading women in med tech? Check out our top women in medical devices list to find out. Special report | Follow @FierceMedDev

@VarunSaxena2: Invitae raises $120M to offer cheap, easy genetic analysis. Story | Follow @VarunSaxena2

@EmilyWFierce: $COV recalled some defibrillator electrodes made by $PHG. Story from MassDevice | Follow @EmilyWFierce

@MichaelGFierce: Stem cell-derived beta cells deliver insulin in response to blood sugar levels. Story | Follow @MichaelGFierce

> In latest M&A news, ConvaTec is up for sale. Story

> St. Jude posts modest gains in Q3 financials led by new products. Article

> Beyond glucose: Developing a diagnostic test for fructose intolerance. More

Pharma News

@FiercePharma: Our newest special report is live! The top 10 most expensive drugs of 2013. Feature | Follow @FiercePharma

@EricPFierce: Novartis says construction delay of Russian plant no big deal, technical changes and not tied to sanctions. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Sanofi wins kudos for airing bribery probe. Phase II? Take to social media. Article | Follow @CarlyHFierce

> FDA grants a combo-med exclusivity wish. Why is that a problem? Story

> Former finance analyst charged in insider trading case. News

> AbbVie-Shire deal in jeopardy, but not necessarily dead. More

Drug Delivery News

> Robert Langer talks science, business and how they intersect. More

> Stem cell-derived beta cells deliver insulin in response to blood sugar levels. Story

> Stealthy, DNA-based 'nano-cocoons' deliver cancer-killing payloads. Report

> Alnylam releases data on its Phase II study of TTR-mediated amyloidosis patients. Item

> Intersect ENT says latest data on dissolving implants for chronic sinusitis are encouraging. Article

Diagnostics News

> Gene sequencing helps Northwestern team diagnose one cause of epilepsy. More

> Exact Sciences nails coveted Medicare coverage for colon cancer DNA test. News

> SomaLogic, CO hospital to develop biomarkers/Dx tests for childhood diseases. Story

> British startup finishes quick and easy Ebola test. Report

> Biocept, Rosetta Genomics want to beef up Dx and biomarker-detection power. Article

Pharma Marketing News

> Teva's SCOTUS appeal is here. But how much can the outcome really affect Copaxone's market share? More

> World's best CEOs? Gilead, Allergan, Novo and Valeant make top 10. Read

> Looking 'beyond the pill'? Start with an app--and then follow this to-do list. Story

> Can Amgen's marketing muscle vault its Humira biosim ahead of rivals? More

> Pictures tell the story in AstraZeneca's breast cancer photo-sharing push. Article

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.